


Timing of Potential HIV Acquisition in People Prescribed HIV PrEP

David H. Spach, MD
Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington

Last Updated: January 4, 2024

Timing of HIV Infection in Persons Prescribed HIV PrEP



Timing of HIV Infection in Persons Prescribed HIV PrEP

1



Prior to Starting HIV PrEP

Taking HIV PrEP

HIV PrEP Discontinued

Time

Timing of HIV Infection in Persons Prescribed HIV PrEP

2



Prior to Starting HIV PrEP

Taking HIV PrEP


HIV PrEP Discontinued

Time



While taking HIV PrEP,

Timing of HIV Infection in Persons Prescribed HIV PrEP



Timing of HIV Infection in Persons Prescribed HIV PrEP

1



Prior to Starting HIV PrEP

Taking HIV PrEP

HIV PrEP Discontinued

Time

HIV Acquisition Prior to Starting HIV PrEP

Baseline HIV Testing




Prior to Starting HIV PrEP


Taking HIV PrEP

Time


HIV Acquisition Prior to Starting HIV PrEP




HIV Antibody Response After HIV Acquisition




HIV p24 Antigen Testing: Time to Positive Test



HIV RNA Testing: Time to Positive Test



HIV Testing: Time to Positive Test



Timing of HIV Infection in Persons Prescribed HIV PrEP

2



Prior to Starting HIV PrEP

Taking HIV PrEP

HIV PrEP Discontinued

Time

HIV Acquisition While Receiving Oral Daily HIV PrEP




Oral HIV PrEP Medication



Period with risk for HIV infection




HIV




Taking Daily Oral HIV PrEP

Time

HIV Acquisition While Receiving Oral Daily HIV PrEP


-  Oral HIV PrEP Medication
-  Wild-type HIV
-  Drug-Resistant HIV



Taking Daily Oral HIV PrEP

Time

HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP




HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP



Long-Acting Injectable Cabotegravir

HIV



Receiving Long-Acting Injectable Cabotegravir (CAB-LA)



Time

HIV Acquisition While Receiving CAB-LA for HIV PrEP



Long-Acting Injectable Cabotegravir

Cabotegravir Kinetics





Time

HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP



Long-Acting Injectable Cabotegravir


Cabotegravir Kinetics




Receiving Long-Acting Injectable Cabotegravir (CAB-LA)

Time

HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP



Timing of HIV Infection in Persons Prescribed HIV PrEP




Timing of HIV Infection in Persons Prescribed HIV PrEP



Oral HIV PrEP Medication



Period with risk for HIV infection




Timing of HIV Infection in Persons Prescribed HIV PrEP



Long-Acting Injectable Cabotegravir



Period with risk for HIV infection



2 months



Taking HIV PrEP

HIV PrEP Discontinued

Time

Timing of HIV Infection in Persons Prescribed HIV PrEP

1



2



3



Prior to Starting HIV PrEP

Taking HIV PrEP

HIV PrEP Discontinued

Time

Acknowledgement

The production of this **National HIV PrEP Curriculum** *Mini-Lecture* is supported by Grant U62PS924588 from the Centers for Disease Control and Prevention (CDC) and U10HA32104 from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS). Its contents are solely the responsibility of the University of Washington IDEA Program and do not necessarily represent the official views CDC, HRSA, or HHS. This project is led by the University of Washington Infectious Diseases Education & Assessment (IDEA) Program.

